STS/EACTS: Important Trials Every Surgeon Should Know About

All of the relevant financial relationships listed for these individuals have been mitigated. Unless otherwise noted, speakers have nothing to disclose.

Moderators

Vinod Thourani, MD
Disclosure(s): Abbott Vascular: Consultant (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); Artivion: Consultant (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); AtriCure: Consultant (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); Boston Scientific: Consultant (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); dasi simulations: Advisory Board (Ongoing); Edwards Life Science: Consultant (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); Jenavalve: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); Medtronic: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing)

Patrick Myers, MD

Presentations

  1. The 5 Year Results of PARTNER 3 Favor More SAVR in Low-Risk Patients
    Michael Mack, MD
    Disclosure(s): Carmat: Corporate Board Member (Ongoing); Edwards Lifesciences: Trial Co-PI (Ongoing); Medtronic: Study Chair (Ongoing)
     
  2. The 5 Year Results of PARTNER 3 Favor More TAVR in Low-Risk Patients
    Gry Dahle, MD, PhD
     
  3. Transcatheter Tricuspid Valve Replacement: Obtaining the Necessary Skills for Success
    James Stewart, MD, FACC
     
  4. Transcatheter Tricuspid Valve Repair: Is This the New Gold Standard Instead of Surgical Repair?
    Gorav Ailawadi, MD, MBA
    Disclosure(s): edwards, Abbott, Anteris, Nyra, Medtronic, Arthrex, J&J, Philips: Advisory Board (Ongoing), Consultant (Ongoing)
     
  5. Hybrid and Surgical AF Ablation: What the Surgeons Need to Know
    Patrick Myers, MD
     
  6. Randomized Trials by Surgeons for Surgeons: CTSN
    Annetine Gelijns, PhD
Activity summary
Available credit: 
  • 1.50 AMA PRA Category 1 Credit
  • 1.50 Participation
Activity opens: 
02/01/2024
Activity expires: 
02/15/2027
Cost:
$0.00
Rating: 
5

Available Credit

  • 1.50 AMA PRA Category 1 Credit
  • 1.50 Participation

Price

Cost:
$0.00
Please login or register to take this course.

All of the relevant financial relationships listed for these individuals have been mitigated. Unless otherwise noted, speakers have nothing to disclose.

Moderators

Vinod Thourani, MD
Disclosure(s): Abbott Vascular: Consultant (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); Artivion: Consultant (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); AtriCure: Consultant (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); Boston Scientific: Consultant (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); dasi simulations: Advisory Board (Ongoing); Edwards Life Science: Consultant (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); Jenavalve: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); Medtronic: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing)

Patrick Myers, MD

Presentations

  1. The 5 Year Results of PARTNER 3 Favor More SAVR in Low-Risk Patients
    Michael Mack, MD
    Disclosure(s): Carmat: Corporate Board Member (Ongoing); Edwards Lifesciences: Trial Co-PI (Ongoing); Medtronic: Study Chair (Ongoing)
     
  2. The 5 Year Results of PARTNER 3 Favor More TAVR in Low-Risk Patients
    Gry Dahle, MD, PhD
     
  3. Transcatheter Tricuspid Valve Replacement: Obtaining the Necessary Skills for Success
    James Stewart, MD, FACC
     
  4. Transcatheter Tricuspid Valve Repair: Is This the New Gold Standard Instead of Surgical Repair?
    Gorav Ailawadi, MD, MBA
    Disclosure(s): edwards, Abbott, Anteris, Nyra, Medtronic, Arthrex, J&J, Philips: Advisory Board (Ongoing), Consultant (Ongoing)
     
  5. Hybrid and Surgical AF Ablation: What the Surgeons Need to Know
    Patrick Myers, MD
     
  6. Randomized Trials by Surgeons for Surgeons: CTSN
    Annetine Gelijns, PhD